Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 16 |
| Active Pipeline (Recruiting Now) | 8 (3) |
| Completed vs Stopped Early | 6 / 2 (12.5%) |
| Median Closed Actual Enrollment | 75 participants |
| Physical Hospital Site Disclosure | 97.9% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| King's College Hospital NHS Foundation Trust | London | 6 |
| Cliniques Universitaires Saint-Luc | Brussels | 5 |
| UC Davis Comprehensive Cancer Center | Sacramento, CA | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07209462 | Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) | Phase II | RECRUITING |
| NCT04663308 | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cho | Phase II | ACTIVE NOT RECRUITING |
| NCT06553768 | Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Phase III | ACTIVE NOT RECRUITING |
| NCT04718961 | A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OH | Phase II | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the Mirum Pharmaceuticals Interactive Dossier, benchmark peers in Gastroenterology, Hepatology, and Renal, or review the Healthcare Price & Patent Cliff Crosswalk.